Biomarin Pharmaceutical (BMRN) Revenue (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Revenue came in at $766.2 million in Q1 2026, up 2.83% YoY from $745.1 million in Q1 2025, and down 12.39% on a QoQ basis from $874.6 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Revenue (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Revenue data on file, last reported at $766.2 million in Q1 2026.
- Quarterly Revenue rose 2.83% year-over-year to $766.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 9.9% YoY) and the FY2025 annual result came in at $3.2 billion, up 12.87% from the prior year.
- Revenue eased to $766.2 million in Q1 2026, from $874.6 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $874.6 million in Q4 2025 to a low of $505.3 million in Q3 2022.
- A 5-year average of $668.0 million and a median of $648.8 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2024 — Revenue rose 28.28% — and 2026, when it rose 2.83%.
- Tracing BMRN's Revenue over 5 years: stood at $537.5 million in 2022, then rose by 20.22% to $646.2 million in 2023, then grew by 15.65% to $747.3 million in 2024, then advanced by 17.03% to $874.6 million in 2025, then declined by 12.39% to $766.2 million in 2026.
- The last three Revenue figures came in at $766.2 million (Q1 2026), $874.6 million (Q4 2025), and $776.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 989.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 989.71 Mn |
| Mar 31, 2026 | 766.21 Mn |
| Dec 31, 2025 | 874.57 Mn |
| Sep 30, 2025 | 776.13 Mn |
| Jun 30, 2025 | 825.41 Mn |
| Mar 31, 2025 | 745.15 Mn |
| Dec 31, 2024 | 747.31 Mn |
| Sep 30, 2024 | 745.74 Mn |
| Jun 30, 2024 | 712.03 Mn |
| Mar 31, 2024 | 648.83 Mn |
| Dec 31, 2023 | 646.21 Mn |
| Sep 30, 2023 | 581.33 Mn |
| Jun 30, 2023 | 595.28 Mn |
| Mar 31, 2023 | 596.42 Mn |
| Dec 31, 2022 | 537.54 Mn |
| Sep 30, 2022 | 505.34 Mn |
| Jun 30, 2022 | 533.80 Mn |
| Mar 31, 2022 | 519.36 Mn |
| Dec 31, 2021 | 449.81 Mn |
| Sep 30, 2021 | 408.74 Mn |